Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease

European Journal of Dermatology

Volumn 13, Issue 3, 2003, Pages 258-260

  Zaccagna, Alessandro ^a   Bertone, Alberto ^b   Puiatti, Paolo ^a   Picciotto, Franco ^a   Sprujevnik, Tatiana ^b   Santucci, Renato ^b   Rossini, Francesco Paolo ^b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Crohn's disease; Infliximab; Neutrophilic dermatoses; Pyoderma gangrenosum; Therapy; Tumor necrosis factor alpha

Indexed keywords

IMIPENEM; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACANTHOSIS; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL EXAMINATION; PYODERMA GANGRENOSUM; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FOOT ULCER; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYODERMA GANGRENOSUM;

EID: 0038540240     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Targan SR, Hanauer SB, van Deventer SJ Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
3. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburg 1 experience. Aliment Pharmacol Ther 2001; 15 (10): 1639-46.
4. Bondeson J, Maini RN. Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract 2001; 55 (3): 211-6.
5. Voigtländer C, Lüftl M, Schuler G, Hertl M. Infliximab (Anti-Tumor Necrosis Factor a Antibody). A novel, highly effective treatment of recalcitrant subcorneal pustolar dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137: 1571-4.
6. Fujino Y. Behcet's disease. Nippon Rinsho 2002; 60 (Suppl. 1): 381-8.
7. Rozembaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002; 61 (3): 283-4.
8. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of Infliximab on threatening panuveitis in Behcet's disease. Lancet 2001; 358 (9293): 1644.
9. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestina Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001; 49 (5): 725-8.
10. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358 (9278): 295-6.
11. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet's syndrome with tumour necrosis factor olpha blocking therapy. Ann Rheum Dis 2001; 60 (6): 637.
12. Griffiths CE. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002; 359 (9303): 279-80.
13. Tutrone WD, Kagen MH, Barbagallo J, Weinberq JM. Biologic therapy for psariasis: a brief history, II. Cutis 2001; 68 (6): 367-72.
14. Chaudari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gattlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: o randomised trial. Lancet 2001; 357 (9271): 1842-7.
15. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treotment af severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26 (1): 27-9.
16. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42 (5 Pt 1): 829-30.
17. Girolomoni G, Abeni D. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 2001; 137 (6): 784-5.
18. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M. Treatment of psoriatic arthritis with anti-tumar necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144 (3): 587-9.
19. Geyer AS, Anhalt GJ, Nousari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 2000; 136 (4): 459-60.
20. Korzenik JR. Infliximab for fistulas: a hole in one? Inflamm Bowel Dis 2000; 6 (1): 62.
21. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340 (18): 1398-405.
22. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7 (4): 323-6.
23. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangenosum. JAMA 2000; 284 (12): 1546-8.
24. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement af Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137 (7): 930-3.
25. Sheldon DG, Sowchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implication and management. Arch Surg 2000; 135 (5): 564-568; discussion 568-9.
26. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant Pyoderma gangrenosum associated with Crohn disease: rapid cure with infliximab. Dermatology 2002; 205 (3): 278-80.
27. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab child with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 34 (5): 558-60.
28. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37 (7): 863-5.
29. Ljiung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha Blockade with infliximab. Scand J Gastroenterol 2002; 37 (9): 1108-10.
30. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999; 13 (1): 65-73.
31. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol 1930; 22: 655-80.
32. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt. Sinai J Med 2001; 68 (4-5): 287-97.
33. Groves RW, Allen MH, Ross EL, Barker JNWN, MacDonald DM. Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecole expression. Br J Dermatol 1995; 132: 345-52.
34. Kupper TS. Immune and inflammatory processes in cutaneous tissues. Mechanism and speculation. J Clin Invest 1990; 86: 1783-9.
35. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000; 9: 1-10.
36. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.